Clinical trial
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV…
NCT00482911 · National Institutes of Health Clinical Center (CC), NIH · Terminated
Key facts
| NCT number | NCT00482911 |
|---|---|
| Title | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma |
| Official title | A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Malignant Conjunctival Neoplasm |
| Intervention type | Drug |
| Interventions | cyclophosphamide, lenalidomide, sunitinib malate |
| Enrollment | 12 |
| Start date | Apr 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jun 5, 2007 |
| Last update posted | Mar 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: